Paid Clinical Trials Akron

Discover 1,546 paid clinical trials in Akron, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,546

Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Akron OH, Cleveland OH, Farrell PA, Wexford PAshow 269 more

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Magnetic Resonance Imaging

Photon Beam Radiation Therapy

Questionnaire Administration

Temozolomide

Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Cleveland OH, Columbus OH, Morgantown WV, Londonshow 34 more

Code:

NCT05552976

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezigdomide

Carfilzomib

Dexamethasone

AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

West Chester OH, London, Ann Arbor MI, Amherst NYshow 35 more

Code:

NCT05711394

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Atogepant

Placebo-Matching Atogepant

Optimizing TreatmentOptimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

Recruiting

PHASE3

Sponsor:

HELP for NOWS Consortium

Location:

Cleveland OH, Kettering OH, Cincinnati OH, Edgewood KYshow 16 more

Code:

NCT05980260

Conditions

Neonatal Opiate Withdrawal Syndrome

Eligibility Criteria

Sex: All

Age: 1 - 48

Healthy Volunteers: Not accepted

Interventions

Symptom-based Dosing Approach

Scheduled Opioid Taper Approach

LuspaterceptA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Recruiting

PHASE3

Sponsor:

Celgene

Location:

Cleveland OH, Detroit MI, Toronto, Chicago ILshow 9 more

Code:

NCT04064060

Conditions

Myelodysplastic Syndromes (MDS)

Beta-thalassemia

Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Luspatercept

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Cleveland OH, Cincinnati OH, Indianapolis IN, Lexington KYshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Cleveland OH, Pittsburgh PA, Detroit MI, Londonshow 68 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

Olaparib

MK-4280

XL092 & NivolumabStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Recruiting

PHASE3

Sponsor:

Exelixis

Location:

Cleveland OH, Buffalo NY, Knoxville TN, New York NYshow 6 more

Code:

NCT05678673

Conditions

Non-Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

XL092

Nivolumab

Sunitinib Malate

Photodynamic TherapyImaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses

Recruiting

PHASE2

Sponsor:

Case Comprehensive Cancer Center

Location:

Cleveland OH

Code:

NCT05923060

Conditions

Actinic Keratoses

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Topical Aminolevulinate

Photodynamic therapy (PDT)

Red light illumination

Quemliclustat & ChemotherapyStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

PHASE3

Sponsor:

Arcus Biosciences, Inc.

Location:

Cleveland OH, Pittsburgh PA, Buffalo NY, Torontoshow 29 more

Code:

NCT06608927

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Quemliclustat

Placebo

Nab-paclitaxel

Gemcitabine